Sagimet Biosciences (SGMT) Stock Price, News & Analysis

Company Overview

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for diseases associated with abnormal lipid metabolism. The company’s primary focus is fatty acid synthase (FASN), an enzyme involved in the production of fatty acids that can contribute to disease progression in certain metabolic and inflammatory conditions.

Sagimet’s lead product candidate is denifanstat, formerly known as TVB-2640. Denifanstat is an orally administered, selective FASN inhibitor being evaluated primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can lead to fibrosis, cirrhosis and other serious complications. The company has also investigated FASN inhibition in additional disease areas, including oncology and dermatological conditions.

Originally established as 3-V Biosciences, Sagimet Biosciences is headquartered in San Mateo, California, and conducts clinical development activities intended to support potential regulatory approval of its therapies. Its research and development programs are focused on translating FASN biology into medicines for patients with significant unmet medical needs.

Key Stats

• Today's Range: $10.80 to $11.40
• 50-Day Range: $7.01 to $11.17
• 52-Week Range: $4.50 to $11.45
• Volume: 1.85 million shs
• Average Volume: 898,921 shs
• Market Capitalization: $689.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.96
• Consensus Rating: Moderate Buy

Sagimet Biosciences Stock Analysis - MarketRank™

Sagimet Biosciences scored higher than 62% of companies evaluated by MarketBeat, and ranked 212th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sagimet Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Sagimet Biosciences has a consensus price target of $27.96, representing about 152.1% upside from its current price of $11.09.

Amount of Analyst Coverage

Sagimet Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sagimet Biosciences are expected to grow in the coming year, from ($1.19) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sagimet Biosciences is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sagimet Biosciences is -8.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sagimet Biosciences has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.38% of the float of Sagimet Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Sagimet Biosciences has a short interest ratio ("days to cover") of 9.58.

Change versus previous month

Short interest in Sagimet Biosciences has recently decreased by 13.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sagimet Biosciences does not currently pay a dividend.

Dividend Growth

Sagimet Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

6 people have searched for SGMT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Sagimet Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $920,491.00 in company stock.

Percentage Held by Insiders

11.50% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGMT
• CIK: 1400118
• Web: sagimet.com
• Phone: 650-561-8600
• Fax: N/A
• Employees: 16
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Sagimet Biosciences: $27.96
• High Price Target: $56.00
• Low Price Target: $10.71
• Potential Upside/Downside: +152.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.96%
• Return on Assets: -30.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 45.03
• Quick Ratio: 45.02

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 344.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.42 per share
• Price / Book: 3.24

Miscellaneous

• Outstanding Shares: 62,160,000
• Free Float: 55,011,000
• Market Cap: $689.35 million
• Optionable: Optionable
• Beta: 3.45